## EXPD: Expeditors International of Washington, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%); PEG 5.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($145.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Here's Why Investors Should Bet on Expeditors International Stock Now**
- Source: Finviz | 20251223T150751 | Bullish | Relevance: 100%
- Expeditors International of Washington (EXPD) is recommended as a strong investment due to robust cost-cutting initiatives, shareholder-friendly actions, and impressive stock performance. The company has seen significant northward estimate revisions, solid stock price appreciation, a Zacks Rank #1, and a consistent positive earnings surprise history. These factors, alongside its commitment to shareholder returns through dividends and buybacks, make EXPD an attractive option for investors.

**2. Ryanair-ESN Partnership Tops One Million Erasmus Students**
- Source: Finviz | 20251223T150752 | Bullish | Relevance: 74%
- Ryanair has successfully carried over one million Erasmus students through its nine-year partnership with the Erasmus Student Network (ESN), highlighting its role in affordable student mobility across Europe. This collaboration provides discounted fares and free baggage, especially during peak travel times like Christmas, benefiting students and strengthening Ryanair's appeal. The airline's stock, RYAAY, has seen a significant 28.9% surge over the last three months, outperforming the industry.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Stifel | $136 | $130 | +5% |
| 2025-12-08 | Morgan Stanley | $95 | $90 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Stifel | main | Hold |
| 2025-12-08 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.01M) |
| Sells | 2 ($0.93M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (-0.9%)
- Blackrock Inc.: 9.2% (-10.1%)
- State Street Corpora: 5.8% (+5.1%)
- First Eagle Investme: 4.7% (+0.0%)
- LOOMIS SAYLES & CO L: 4.3% (+1.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 5.2x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 5.25 signals overvaluation risk, limited margin of safety. Forward P/E 25.4x stretched relative to 2% growth. Quality metrics strong (ROE 36%, ROA 14%). Analyst sentiment positive (2 raises, avg +5%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.6B |
| Beta | 1.14 |
| 52W Range | $100.47 - $155.04 |
| Short Interest | 4.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.25 |
| Forward P/E | 25.4 |
| Current P/E | 25.8 |
| YoY Growth | 1.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.4% to -1.2% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.57), momentum weakening. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.19% (CS: 46) | Neutral |
| RSI_14 | 63.5 | Neutral |
| MACD Histogram | -0.57 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.103x | Above |
| vs SMA200 | 1.250x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $151.73
- **Stop Loss:** $145.75 (3.9% risk)
- **Target:** $157.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 150
- **Position Value:** $22,759.50
- **Portfolio %:** 22.76%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-24 (Est: $1.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.39 | $1.64 | +18.1% |
| 2025Q2 | $1.24 | $1.34 | +7.9% |
| 2025Q1 | $1.35 | $1.47 | +9.1% |
| 2024Q4 | $1.44 | $1.68 | +16.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*